London, January 17, 2026, 07:58 GMT — The market has closed.
- GSK shares fell 1.7% in London on Friday, marking a third consecutive session of losses.
- Filings revealed that senior executives and a director chose to reinvest their dividends into shares and U.S.-listed ADSs.
- Investors are shifting focus to early-February earnings and upcoming U.S. drug-approval news.
Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day average of 8.2 million.
This matters because the selling is hitting before the drugmaker’s full-year results drop in early February, a time when the market often penalizes even minor disappointments. The surge in volume indicates some investors are making substantial moves, not just casually exiting.
Thursday didn’t offer any relief. Shares dropped 1.73% to 1,848 pence, lagging behind the FTSE 100, which climbed 0.54%. Trading was light, with just 4.8 million shares changing hands—well below the usual volume.
A U.S. regulatory filing Friday revealed non-executive director Hal Barron — classified as a PDMR, a senior insider — bought roughly 2,832 American depositary shares (ADSs) at $50.2949 each on Jan. 14. The purchase came via dividend reinvestment from dividends paid Jan. 8. The filing also noted similar ADS buys by group general counsel James Ford and chief digital and technology officer Shobie Ramakrishnan, linked to the same dividend reinvestment.
A separate UK regulatory filing revealed that President of Corporate Development David Redfern and company secretary Victoria Whyte each purchased small amounts of ordinary shares at £18.845 on Jan. 9. These buys were made through dividend reinvestment within an ISA, a tax-advantaged UK savings account.
Beyond individual company filings, investors are eyeing a changing U.S. approval landscape. Six industry sources told Reuters on Friday that some drugmakers are nervous about legal risks tied to the FDA’s National Priority Voucher Program, which speeds decisions to one or two months. So far, the agency has handed out vouchers for 18 drugs, including products from GSK and others like Merck, Johnson & Johnson, and Regeneron. Greg Graves, a senior partner at McKinsey’s U.S. life sciences division, said, “It’ll be hard to unmake history” if these faster reviews stick around without sacrificing scientific rigor. Reuters
GSK’s ADSs dipped to $48.22 late Friday in New York, slipping roughly 1.8% from the previous close.
GSK will release full-year and Q4 results on Wednesday, Feb. 4. Investors will be watching closely for updates on 2026 guidance and pipeline timing—those details often spark sharp moves in an otherwise sluggish stock.
The risk lies in that forward-looking outlook. Regulatory deadlines may slip, pricing pressure could surge quickly in the U.S., and a few problematic trial results might divert focus from the dividend narrative.
London trading kicks off again Monday, but U.S. markets remain closed for Martin Luther King Jr. Day, potentially thinning ADR-linked activity and slowing price discovery across the Atlantic. The real challenge arrives with the next full London session, followed by the February 4 earnings figures.
